US20140212405A1

US20140212405A1 - Fibrinolytic/Proteolytic Treatment of Myofacial and Neuropathic Pain and Related Conditions

Info

Publication number: US20140212405A1
Application number: US13/751,673
Authority: US
Inventors: Blair Lamb
Original assignee: 2294719 Ontario Ltd
Current assignee: 2294719 Ontario Ltd
Priority date: 2013-01-28
Filing date: 2013-01-28
Publication date: 2014-07-31
Also published as: US20150359860A1; AU2014210332A1; EP2948171A1; EP2948171A4; CA2899234C; AU2014210332B2; CA2899234A1; US9901626B2; WO2014113878A1

Abstract

A method is disclosed to dissolve protein deposited in muscle. The method includes the step of administering an effective amount of an agent selected from the group consisting of fibrinolytics, proteolytics, photolytic and magnelytic agents.

Description

BACKGROUND

The present invention relates to the fields of chemistry and physiology, particularly protein chemistry and more particularly lipolytic, proteolytic and fibrinolytic compounds.
Fibrin is the basic building block of scar tissue that builds in the human or animal body. Although other proteins play a similar role in the body, fibrin is the major unit of scar deposition.
Some of the most studied areas where fibrin and other proteins have been shown to be deposited is in the blood vessels of the body, particularly the arteries. For example, U.S. Pat. No. 4,039,658 describes a new fibrinolytic enzymatic product having also anticoagulant properties is recovered from bile. It can be further purified to yield several fractions, all having similar activities, their molecular weights varying between about 5,000 and 50,000. The product or its fibrinolytically active derivatives are used to dissolve fibrin and inhibit blood coagulation in vivo or in vitro.
U.S. Pat. No. 4,055,635 describes a fibrinolytic pharmaceutical composition in unit dosage form suitable for administration by injection to humans which comprises an amount of a water soluble complex of a proteolytic enzyme sufficient to achieve the desired degree of fibrinolysis on administration to a human and linked covalently to a water-soluble polymeric substance having a molecular weight of from 10,000 to 500,000. The enzyme and the polymeric substance are present in the ratio of 1:2 to 1:50 and the composition is substantially free of unreacted enzyme.
U.S. Pat. No. 6,440,414 discloses a pharmaceutical composition comprising a metalloproteinase fibrinolytic agent, a zinc stabilizer and, optionally, a bulking agent, in a pharmaceutically-acceptable buffer. This metalloproteinase fibrinolytic agent comprises a specific amino acid sequence.

SUMMARY

In one aspect of the invention a method to dissolve protein deposited in muscle is provided. The method comprises administering an effective amount of an agent selected from the group consisting of fibrinolytics, proteolytics, photolytic and magnelytic agents.
In a preferred embodiment, the muscle is skeletal muscles of the spine and/or limbs to alleviate pain.
In another preferred embodiment, the agent is fibrinolytic.
In another preferred embodiment, the agent is proteolytic.
In another preferred embodiment, the agent is a photolytic agent.
In another preferred embodiment, the agent is a magnelytic agent.
In a further preferred embodiment, the agent is administered topically, intravenously, orally, or mucosally.
In another preferred embodiment, the agent is administered via a rectal suppository, a nasal spray, optic drops, topical formulation, a vaginal composition or an intravenous composition.
In another preferred embodiment, the agent is administered via a rectal suppository.
In another preferred embodiment, the agent is administered via a nasal spray.
In another preferred embodiment, the agent is administered via optic drops. In another preferred embodiment, the agent is administered via a vaginal composition.
In another preferred embodiment, the agent is administered via an intravenous composition.
In another preferred embodiment, fibrinolytic is administered at a concentration in the range of about (0.1) to about (2 mg/ml) is a physiologically acceptable solution.
In another preferred embodiment, the fibrinolytic agent is Serrapeptase and/or Nattokinase.
In another preferred embodiment, wherein 5000 IU (international units) of Serrapeptase is administered is administered orally in the form of one to four tablets three times daily.
In another embodiment, 5000 IU Nattokinase is administered is administered orally in the form of one to four tablets three times daily.
In yet another embodiment, the agent is formulated to comprise, per 30 mls., serrapeptase 10-50,000 IU and/or nattokinase 10-50,000 IU and/or lipase 10-50,000 IU and/or Rutin 10-50,000 IU and/or amla 10-50,000 IU and other proteases and/or fibrinolytics
In another preferred embodiment, the agent is formulated for mucosal or vaginal or rectal administration wherein the agent comprises a solution having the components mixed in a sterile solution of water producing a concentration of about 0.1% to 5%. A stronger or weaker solutions may be used to reduce or enhance effects and other mixing agents may be used to enhance absorption transdermally such as DMSO
In another preferred embodiment, the agent is formulated for pulmonary and nasal administration wherein the agent is -delivered by a lung and nasal vaporizer inhaler (respectively) in a metered dosing mechanism.
In another preferred embodiment, the agent is mixed in sterile solution of water producing a concentration of about 0.1% to 5%. A stronger or weaker solution may be used to reduce or enhance effects and the solution optionally contains other mixing agents used to enhance absorption transdermally such as DMSO.
In another preferred embodiment, an inhaler is provided that contains serrapeptase 10-50,000 IU to be mixed and/or nattokinase 10-50,000 IU to be mixed and/or lipase 10-50,000 IU to be mixed and/or Rutin 10-50,000 IU to be mixed and/or amla 10-50,000 IU to be mixed other proteases. The fibrinolytics may be added or used individually.
In another aspect a method is provided to treat consumable animal meat said method comprising administering an effective amount of the agent to dissolve protein deposited in skeletal muscles, organs or tissues of farm animals to improve or increase perceived improved quality of farm animal products.

DETAILED DESCRIPTION

As used herein, the term “fibrinolytic” refers to any natural or synthetic substance, any recombinant protein, and any fragment, natural or synthesized that has fibrinolytic activity.
The present invention is founded on the concept that, in certain situations, fibrin deposits may actually impair the healing process. In the case of the skeletal muscles or smooth muscles, the fibrin deposition process is complicated. Any injury including direct trauma, repetitive activity, exercise to the muscle may trigger a shortening of the muscle that may then cause the deposition of fibrin/and or other proteins into key areas or shortened areas of the muscle causing scar formation, trigger point formation, and difficulty with re-elongation of the muscle to its normal or maximal length. This may cause sustained or prolonged shortening of skeletal muscle. Any muscle in the body may be affected in this way including those of the spine, limbs, smooth muscle, sensory organs, organs, head and face.
This sustained shortening of muscle can contribute to a variety of different pathologies. These pathologies may then start a chain of events that may then cause other conditions, which could be related to chronic pain and/or disease.
As a simple illustration, a person may lift a heavy rock and injure the hamstring muscle in one of their legs. Over the course of a few days, the injury often triggers shortening of the hamstring in the area of significant injury. This may then lead to the deposition of fibrin and other proteins into the muscle causing the formation of a scar. This prevents the return of the muscle to its previous length, but also effects normal functionality of shortening and elongation of the muscle to create power. Further, the area where the fibrin has been deposited may contribute to wasting, trigger point encapsulation, excessive muscle shortening, and chronic tendon elongation with traction, injury or strain. As a result, the muscle may become weaker in these areas. This sustained shortening may cause persistent pulling on the origin or insertion of a muscle, leading to partial or complete tearing of the tendon. The fibrin deposited in the muscle may form an area of the muscle staying contracted or shortened. Inside the contracture will often be excess current or electrical potential. These areas or points of abnormal electrical potential (excessive) are often medically named as trigger points. These trigger points can become quite rigid and resistant to therapy by stretching or other exercise. If several of these trigger points or large section of fibrin are deposited in the same muscle, gross weakness and dysfunction may occur in the muscle. A hamstring injury leading to this shortening and scarring process may occur from one single injury or repeated small injuries causing an accumulation of small injuries into one compounded injury. The result is similar; deposition of fibrin and other proteins into the shortened, injured muscle/tendon structure causing encapsulated excessive electrical activity, less functionality of the muscle, chronic shortening of the tendon, tendon inflammation, muscle weakness with risk of tear or strain.
Once muscles shorten then a set of other complications may occur. The shortened muscle can cause chronic traction to its tendon causing tendonitis, and even premature rupture. It may cause compression or mal-tracking of the joints above or below the origin and insertion leading to premature joint wear, cartilage wear, arthritis, joint pain, and swelling. It may cause muscle weakness, pain and referred pain from the trigger point to other body areas as the stretch of the trigger point from the attempted elongation of the muscle signals referred pain. This is unique in trigger point description and understanding. One example is that of the gluteus medius trigger points, which refer to the sole of the foot, causing plantar fasciitis. One would suspect a foot origin, when in fact the gluteus medius refers to the sole of the foot. A scar within the gluteus medius sustains elongation with walking which triggers a referral of pain perceived into the foot causing an apparent foot pain. The origin of the actual pain, however, is in the gluteus medius where treatment should be directed.
In the spine, which includes the cervical, thoracic spine, and the lumbosacral spine, the problem can be more complex. A typical example of spinal scar formation occurs when the muscles of the spine are injured by either single injury, repeated injury or over years of daily living. The muscles respond following the same pattern with shortening and eventual scarring from the laying down of fibrin/proteins. The main difference in the spinal muscles is that the deepest muscle layers (often known as the intrinsic spinal muscles-multifidus, rotator brevis and longus for example) can form “super-scars” or super-contractures. This is where most of the muscle becomes a solid scar where by fibrin and/or other proteins have been deposited to such a degree that the muscle functions poorly or not at all. Beyond this, there is significant shortening with impact on the other spinal elements around or near the deep spinal muscles affecting many other connected functions of the body.
The spinal elements include the spinal vertebrae, the spinal discs, the spinal cord, the spinal nerve roots, spinal ligaments, the spinal articulating joints (including the cartilage) as well as the deep and superficial muscles of the spine. These intrinsic spinal muscles (often known as the multifidus and the deep rotators, but also including other deep spinal muscles not mentioned) can become completely encapsulated in a scar or scars made up of fibrin and other proteins. Once these super contractures form on/in the deep muscles, they can cause compression of the spinal discs that can then lead to disk degeneration, bulging, herniation, and/or sequestration leading to other spinal disease or effects. The consequences of these disk injuries can then lead to spinal cord and spinal nerve root compression, injury or even paralysis. The spinal neuropathies can then lead to pain conditions or other diseases that can then cause further pain or diseases distally.
The superficial layer of spinal muscle may also form scar tissue that can contribute to compression or mal-position of vertebrae or other spinal elements leading to conditions such as scoliosis, disk compression, facet joint compression, spinal cord compression or irritation, nerve root compression or irritation and then go on to cause local or distal pathology or pain.
The next component in understanding the injury mechanism is that of “Cannon's Law” where tissues that are deprived of their sensory or motor component become supersensitive. In Cannon's Law, a spinal nerve that is compromised may cause electrical abnormalities down an arm or leg, which may then lead to significant and or temporary or permanent changes in the arm or leg. This is typically the result of altered nerve signal to the tissue causing a change in electrical behavior of the muscle or tissue.
In the case of skeletal muscle, where motor nerve impingement may be impaired, the muscles in the body may persistently shorten due to the lack of motor nerve signal that is normally transmitted to the muscle. A common case example is that of tennis elbow where the fourth, fifth or sixth motor nerve root may be impaired or compromised by a bulging disc in the neck (caused by shortened and/or scarred deep spinal muscles). This results in the forearm muscle shortening causing excessive and/or persistent muscle workload. That in turn causes inflammation and injury leading to the deposition of fibrin and or other proteins into the forearm muscle. The muscle shortening followed by the deposit of fibrin/proteins in the forearm extensors may then cause “trigger point” formation in the extensors of the forearm. This may then cause a traction injury to the tendon of the extensor causing tendinitis of the forearm extensor. This muscle shortening in the forearm extensor may also compress the elbow joint or cause abnormal tracking of the elbow joint leading to pain, crepitus and even degeneration of the elbow joint. It may also cause a similar compression syndrome in the wrist causing crepitus, pain or premature degeneration of the wrist joints.
The present invention comprises the use of enzymes and/or other chemicals, and/or light therapy and/or magnetic therapy to dissolve fibrin and/or other proteins deposited in skeletal muscle of the spine and or limbs. It also applies to the benefits that are derived directly or indirectly from the dissolution of these proteins in the spine and/or limbs or elsewhere. The enzymes used to dissolve fibrin are called fibrinolytics, and enzymes that are used to dissolve all proteins as a group are called proteolytics. Light or magnetic therapy having these effects are called photolytic effects or magnelytic effects respectively. These enzymes may be applied topically, through IV, infusions, orally, inhaled or sprayed through the nasal or lung passages, taken rectally, through the urethra into bladder, via ocular eye drops, via otic drops, topical drops, transcutaneous spray, through the vagina into uterus/vagina or injected directly into the tissues for local affect, which could be muscular, or into sites where scars exist. In addition, fibrinolytic therapiesmay be applied to chest cavity, abdominal cavity, cranium for affects on organs or brain tissue. The benefits direct or indirect derived from these therapies can be seen in accordance with the methods and compositions of the invention. The application of a light source or magnetic source over the scarred areas may also reverse of this process.
For example, the ingestion of fibrinolytics to dissolve fibrin that has deposited in a neck may help to treat neck pain. However, beyond the neck pain dissolving the fibrin in the neck may also help to dissolve the scar tissue that compresses the disks in the neck, allowing for recovery of disk disease and the referred pain related to the disc disease, such as the nerve root impingement in the neck, leading to arm pain and other conditions. Disease processes related to neuropathy caused by this process are also part of the invention.
Therefore, the dissolution of fibrin and other proteins (deposited in the form of scar tissue eventually leading to spinal compression and then to other conditions that could be in the nature of pain and/or disease) could be treated or reversed by this process.
The ingestion of fibrinolytics/proteolytics for the purpose of remodeling of fibrin and/or the other proteins in the musculoskeletal/smooth muscle system may have direct benefits or indirect benefits or both. Further, the use of fibrinolytics/proteolytics for purpose of remodeling of the fibrin/protein deposition in the organs, brain, may also have direct or indirect benefits in disease, illness or injury.
The present invention can be used to provide many different types of benefits to animals, including humans, in need of such therapy. For example, the methods and compositions can be used to dissolve, lyse, cut, remove, and/or mobilize scar tissue (fibrin/protein deposits) on the spine or limb muscles that cause shortening and reduced movement of muscle. Shortened muscles compress joints causing persistent or recurrent joint compression leading to premature joint wear, cartilage wear and eventually osteo-arthritis treatment. The invention can also be used to treat spinal joint compression leading to spinal joint compression, disk compression, disk wear, disk herniation, disk sequestration, spinal stenosis, spinal nerve and spinal cord compression or irritation from disk, bone entrapment caused by shortened muscles with scar, and the complications of the spinal cord and/or nerve root compression and/or irritation such as vertigo, tinnitus, headaches, TMJ or jaw dysfunction RSI, carpal tunnel, ulnar neuritis, fibromyalgia, plantar fasciitis, tennis elbow, golfers elbow, reflex sympathetic dystrophy, CRPS (Chronic Regional Pain Syndrome), all tendonitis, joint stiffness, joint pain, muscle weakness, performance enhancement, constipation from neuropathic benefits from the spine and/or ingestion into gut and/or smooth muscle performance benefits, all spinal pain, sciatica, hip-spine syndrome, spinal mediated angina/vasomotor angina, chest disease, lung disease, asthma, palpitations, heartburn, reflux, costal chondritis, intercostal rib/muscle pain, hip pain, erectile dysfunction, prostate dysfunction, pancreatic dysfunction, deafness, visual effects/deficits, olfactory effects/deficits, adrenal dysfunction, sleep enhancement or sleep pattern normalization. It is also useful in treatment of Depuytrens contractures, post-op scarring from actual surgery-direct dissolution/de-scarring effect, cosmetic facial wrinkles by local muscle relaxation/scar removal effect (topical, oral, direct inject, IV) or by neuropathic pain from spine (usually C1-C3).
The invention can also be used to cause or to allow organ remodeling and repair (heart, liver, lung, kidney, brain, pancreas, spleen, skin, bladder, prostate, breast) from direct action from fibrinolytics/proteolytics, and/or treat or mitigate the complications of diseases of these organs: in diabetes by improving pancreatic vascular disease thereby reversing pancreatic insufficiency/dysfunction or by remodeling or repairing the pancreas; in adrenal disease by improving adrenal vascular disease thereby reversing adrenal dysfunction or by remodeling or repairing the adrenal gland; in cardiac disease by improving cardiac vascular disease thereby reversing cardiac dysfunction or by remodeling or repairing the heart and/or vascular tissue; in Alzheimer's disease/dementia's by the dissolving of protein/fibrin deposits in brain tissue or by remodeling or repairing the brain, in spinal cord scarring by dissolving the fibrin/proteins deposited in or around the spinal cord. The present invention is also thought to have anti-cancer effects, primarily as a result of the use of fibrinolytics or secondarily from anti-neuropathic effects from treating spine/peripheral neuropathy.) Neuropathy may initiate or promote neoplastic changes through chronic inflammation or tissue changes. The treatment or prevention or reversal of neuropathy that may lead to reduced risks of cancer or treat cancer are part of the invention. In addition, fibrinolytic/proteolytic activity may have direct anti-cancer effects related to reduced inflammation both regionally or globally within the body.
Other positive effects include visual benefits from macular degeneration and/or from visual accommodation benefits from aiding in relaxation of muscles affecting the lens of the eye, thereby preventing, treating presbyopia or other age-related eye diseases, deafness by reducing the scar formation within the bones/tissues of the auditory complex, tinnitus by reducing the scar formation within the bones/tissues of the auditory complex, and vertigo by reducing the scar formation within the bones/tissues of the auditory complex.
As stated above, the invention applies to all types of animals. Veterinarian applications for pain relief, and disease treatment or prevention are included within the scope of the invention. Feeding or applying the composition to farm animals such as cows, pigs, chickens, pork, lamb to aid in tenderness of meat for consumption or reduce scar formation in the animals for both health of the animal and improvement in the quality of the meat are included within the scope of the invention.
Other positive effects include sleep enhancement by reducing muscle tension (from fibrinlysis) allowing for normalization of sleep pattern, stroke and heart attack prevention and treatment, constipation prevention and treatment, thyroid gland dysfunction, hypothyroid and hyperthyroid-(fibrinlysis in the gland and/or within its blood supply.)
The invention may also be useful for the treatment of vocal cord scarring by dissolution of fibrin/proteins deposited in or around the vocal cord tissue and similarly for pulmonary fibrosis, COPD and/or asthma by dissolution of fibrin/proteins deposited in lung tissue.
The invention may also lead to improvement of taste from smell by dissolving fibrin and other proteins deposited in sinus and nasal tissue directly or indirectly by improved neurological function from dissolution of scar affecting the nervous system related to smell from spine or brain, and improve taste in thermal taste buds by dissolving fibrin and other proteins deposited in and around the taste bud tissue directly or indirectly by improved neurological function from dissolution of scar affecting the nervous system related to taste from spine or brain, improvement in ability to swallow, dysphagia by dissolution of fibrin/proteins deposited in smooth muscle related to the motility of the pharynx and esophagus in swallowing or directly/indirectly by improved neurological function from dissolution of scar affecting the nervous system related to swallowing from spine or brain, or oral and esophagus tissue directly or by improvement of vascularity of the throat/esophagus thereby improving circulation to throat/esophagus and functionality of throat/esophagus.
Other advantages may include improvement in general gut motility by dissolution of fibrin/proteins deposited in smooth muscle for motility, or indirectly by improved neurological function from dissolution of scar affecting the nervous system related to gut motility from spine or brain or, or large or small intestine tissue, sigmoid colon directly or by improvement of vascularity of the gut thereby improving circulation to the gut and functionality of the gut, or directly/indirectly by improved neurological function from dissolution of scar affecting the nervous system related to the gut (large and small intestine, sigmoid colon) from spine or brain, improvement in renal function by dissolution of fibrin/proteins deposited in smooth muscle of renal system, kidney tissue, ureter, bladder, urethra via motility, or or directly/indirectly by improved neurological function from dissolution of scar affecting the nervous system related to the urological system (kidneys, ureters, bladder, urethra) from spine or brain, or kidney tissue directly, or by improvement of vascularity of the kidney thereby improving circulation to kidney and functionality of kidney, improvement in adrenal function by dissolution of fibrin/proteins deposited in smooth muscle of adrenal system, adrenal tissue via motility, or directly/indirectly by improved neurological function from dissolution of scar affecting the nervous system related to the adrenal gland and system from spine or brain, or adrenal tissue directly, or by improvement of vascularity of the adrenal gland thereby improving circulation to adrenal and functionality of adrenal gland, improvement in pancreatic function by dissolution of fibrin/proteins deposited in smooth muscle of pancreatic system, pancreatic tissue via motility, or or directly/indirectly by improved neurological function from dissolution of scar affecting the nervous system related to the pancreas and pancreatic system from spine or brain, or pancreatic tissue directly, or by improvement of vascularity of the pancreas thereby improving circulation to pancreas and functionality of pancreas, improvement in liver and gallbladder function by dissolution of fibrin/proteins deposited in smooth muscle of the liver and gallbladder system, liver and gallbladder tissue via motility, or or directly/indirectly by improved neurological function from dissolution of scar affecting the nervous system related to the liver and gallbladder from spine or brain, or liver and gallbladder tissue directly, or by improvement of vascularity of the liver and gallbladder thereby improving circulation to liver and gallbladder and functionality of liver and gallbladder, improvement in lung function by dissolution of fibrin/proteins deposited in smooth muscle of the lung, lung tissue via motility, or directly/indirectly by improved neurological function from dissolution of scar affecting the nervous system related to the pulmonary system from spine or brain, or lung tissue directly, or by improvement of vascularity of the lung thereby improving circulation to lungs and functionality of the lungs. Also included are improvements in cardiac function by dissolution of fibrin/proteins deposited in cardiac muscle of the heart, by improving conduction within the cardiac tissue by dissolving scar tissue that may contribute to various arrhythmias. There may also be benefits to the spine or cardiac tissue directly or by improvement of vascularity of the heart thereby improving circulation to the heart and functionality of the heart.
The invention also may be applicable to improvement in all brain function by dissolution of fibrin/proteins deposited in brain tissue, or by improving conduction within the brain tissue by dissolving scar tissue which may contribute to various seizures/abnormal brain activity including headache, behavioral, and cognitive effects. There may also be benefits to the spine that may improve brain function, brain disease, headache, facial pain, or brain tissue directly, or by improvement of vascularity of the brain thereby improving circulation to brain and functionality of the brain.
The invention may also lead to improvement in prostate function by dissolution of fibrin/proteins deposited in smooth muscle of prostatic system, or prostate tissue directly, or directly/indirectly by improved neurological function from dissolution of scar affecting the nervous system related to the prostatic system from spine or brain or by improvement of vascularity of the prostate thereby improving circulation to the prostate and functionality of prostate and also improvement in the ovary and fallopian tube function by the dissolution of fibrin/proteins deposited in the smooth muscle of ovary or fallopian tubes. The invention also may lead to improvement in ovarian, uterine, fallopian tube function by dissolution of fibrin/proteins deposited in smooth muscle of the female reproductive system or directly/indirectly by improved neurological function from dissolution of scar affecting the nervous system related to the female reproductive system from spine or brain, The invention may lead to improvement of vascularity of the ovary or fallopian tube thereby improving circulation to the ovary or fallopian tube and functionality of ovary and fallopian tube allowing for better fertility, general function, cycle function and/or delay in menopause.
In another aspect, the invention provides improvement in testicular function by the dissolution of fibrin/proteins deposited in smooth muscle of testicles, vasculature, and all spermatic transport tubular structures or directly/indirectly by improved neurological function from dissolution of scar affecting the nervous system related to the male reproductive system from spine or brain.
In a further aspect, there is provided direct/indirect benefits to the testicular/tubular tissue directly, or by improvement of vascularity of the testicular system thereby improving circulation to the testicles and functionality of testicles allowing for better fertility, function both hormonal and related to fertility.

EXAMPLES

Example 1

A 50-year-old male suffered from chronic joint-pain for three years. The complaints are sore knees, sore hips, and sore low back. X-rays showed early changes of arthritis with sclerotic changes on x-rays in the knees and hips. Examination demonstrates scar formation, or trigger point formation detected in the muscles of the thighs and calves, swelling of the knees and tenderness in both hips with bursitis. He also has low back pain bilaterally involving much of the lumbar spine. MRI of the spine demonstrates compression of L1-S1 disks in vertebrae with multiple nerve roots compressed, likely contributing to neuropathic pain into his legs. The patient complains of numbness and tingling in both legs and feet and walks with great difficulty. The patient began oral fibrinolytic care starting with a low dose and gradually increasing to optimal dosing. Over the course of three months, the patient noticed a decrease in swelling in both knees, decreasing pain of the low back, hips in the areas. His physician was able to demonstrate dissolution of scar detection or trigger point detection in the muscles of the thighs and calves and paraspinally. Over the course of two years, repeat MRI imaging demonstrated reversal of disk degeneration with increase in space between vertebrae. There was a reversal of nerve root entrapment within the lumbar spine at all sections. The patient had complete clearing of symptoms of numbness and tingling in the legs and feet, and his balance return to normal, and his gait and strength return to normal. The topical application of fibrinolytic care over the joints, specifically, the need joint, noted an accelerated benefit in the area. The injection of a liquid fibrinolytic/proteolytic into the deep spine where the intrinsic spinal muscles were located greatly accelerated the dissolution of the scar tissue in the muscles of the deep spine and this was measured on repeated spinal muscle biopsy.

Example 2

A 55-year-old female presented with weakness in both legs, ataxic gait, pain and numbness and burning of both legs and the pelvic area. Examination demonstrated pain and tenderness in the thoracic spine with retrolisthesis palpable at T5-T8. MRI examination demonstrates compressed discs from T5-T8. Between T5-T6 and T6-T7, two discs were herniated forwards onto the spinal cord touching the spinal cord. This was assigned as the major cause of the patient's lower body disability. The patient was biopsied paraspinally in the thoracic spine, and was found to have severe scarring in the upper back around the area of spinal pathology. She was injected with a fibrinolytic/proteolytic solution into the paraspinal muscles both superficially and deep going through all five layers of spinal musculature. Scarring was felt through the biopsy at all levels. One week after the spinal injections, she had normalization of positioning of the thoracic vertebrae, 80% improvement in her lower body pain, near normalization of her walking ability, normalization of her ataxic gait to normal balance state, complete resolution of numbness and tingling in the lower body, and the re-biopsy of the thoracic spine demonstrated resolution of all scar tissue. MRI of the spine demonstrated correction of the retrolisthesis, great improvement in the spinal compression and decompression of the herniated discs off the spinal cord. The spinal stenosis seen on MRI had greatly improved. Over the course of 6 to 12 months, she continued to improve and made a full recovery.

Example 3

A 75-year-old Scottish male presented with right-handed Depuytrens contractures over the right fourth and fifth metacarpal palmar surface. The individual had curvature of the fourth and fifth digits due to the contractures in the palm of the hand. He was unable to straighten his fingers. He started on oral fibrinolytics and topical lotion made with fibrinolytic contents that he applied three times a day to the palmar surface of his hand. Over the course of three months, he had gradual improvement in range of motion of his hand in digits, and was able to return near full range of motion to his right hand digits and palm.

Example 4

A 35-year-old female had endometriosis and underwent open pelvic surgery with surgical removal of the endometriosis with ablation of endometrial lesions. This resulted in abdominal pain due to scarring from both the surgery and the disease itself. She suffered chronic abdominal pain with intermittent bowel symptoms. She was treated with both an oral fibrinolytic/proteolytic and an injection of fibrinolytic/proteolytic trans-abdominally into her pelvic cavity once every two weeks, such that it could gradually dissolve scar tissue that had formed within the abdominal cavity around bowel, uterus, ovaries, kidneys and other abdominal structures. She noted gradual improvement over three months in her abdominal pain, abdominal tenderness, bowel function, and general well-being in her nominal and pelvic cavity.

Example 5

A 55-year-old female had wrinkles in the skin of her forehead, around the outer canthus of her eyes and had classical smoking lines around her mouth area. She was given the option of the injectible fibrinolytic/proteolytic enzyme to inject into the muscles of the face, such that the scar would be dissolved in the muscles would relax or a topical cream made of similar fibrinolytic/proteolytic enzymes to her facial area. She chose to use the cream around the area of her mouth and eyes. The injection was performed in her forehead. She had great improvement and reduction in the appearance of the wrinkles in all areas.

Example 6

A 52-year-old man suffered from systemic lupus affecting the kidneys and brain. The scarring lesions were detected within the brain on MRI. It was suspected that these could be a risk for seizures or triggering seizures as he had one seizure. Furthermore, his kidney function had greatly reduced and MRI of the kidneys had demonstrated the appearance of scarring in the kidney structure. He had reduced kidney function as demonstrated on greatly elevated creatinine and urea. This was present for several years. He was treated with intravenous delivery of fibrinolytic/proteolytic enzymes to digest the proteinaceous scarring suspected in these two areas. He was treated weekly by infusion. After one month, his serological testing demonstrated a normalization of his creatinine and urea function in the kidneys. MRI of the brain demonstrated reduction in scar formation seen on MRI. Treatment continued for total of six months. Over two years, the patient has not had any seizure activity since and his kidney function has maintained within normal ranges.

Example 7

A 45-year-old female who was slightly obese at 5′2″ and 175 lbs. with a history of fibromyalgia developed non-insulin-dependent diabetes. She had 17 of 18 positive trigger-points (according to the ACR criteria of 1990 for fibromyalgia syndrome) three years ago. She was treated with oral diabetic medications. Her fasting blood sugars were elevated in the range of 10 to 15 (Canadian units normal is less than 6.0) and were not in the normal therapeutic range. MRA imaging of her pancreas suggested possible impaired arterial vascular supply to the pancreas itself. She was treated with oral fibrinolytic/proteolytic care for six months. Over the course of six months she had monthly serology, weighing in, an examination of are trigger points for fibromyalgia. Over the course of six months and monthly examinations, she had a progressive reduction in trigger point positivity for chronic pain in fibromyalgia, and progressive improvement in her blood sugars with 15 pounds of weight loss. Her fasting blood sugars normalized to the range of 4 to 6 in Canadian units. Her weight had dropped to 160 pounds. MRA imaging of the pancreas demonstrated what appeared to be normalization of arterial flow to the pancreas. The same treatment could be applied to patients with similar problems of the liver, spleen, kidneys, testicles, ovaries, with resultant improvement in function of the corresponding organs. We see improvement in liver function in individuals with a history of hepatitis and abnormal liver function. We see an improvement in creatinine and urea in the history of people with elevated creatinine levels. We see an improvement in both sperm production and quality in males with the history of infertility. In some females with a history of infertility, improvement is seen in ovulation through improved vascularity to the ovaries. It should be clear that the combination of improved vascular status and dissolution of deposited scar tissue is likely working in combination to aid in the improvement of these organs. However independently, these actions could or should be of benefit.

Example 8

A farmer with 100 head of adult cattle gave 50 head of cattle oral fibrinolytics mixed in with the cow feed for three months prior to slaughter. The other head of cattle were fed untreated cattle feed. After slaughter, it was found that the treated cattle (with fibrinolytics) had softer, more tender meat that was more flavorful and perceived to be of a much higher grade of meat. Similar findings were found in the other parts of the cattle such as tongue, brain and the leather derived from the cattle was found to have less irregularities, was generally stronger, but of a softer hide of leather.

Claims

1. A method to dissolve protein deposited in muscle, said method comprising administering an effective amount of an agent selected from the group consisting of fibrinolytics, proteolytics, photolytic and magnelytic agents.

2. A method according to claim 1, wherein the muscle is a skeletal muscle selected from the group consisting of the spine and the limbs, and wherein said agent alleviates pain.

3. A method according to claim 1 wherein the agent is a fibrinolytic.

4. A method according to claim 1 wherein the agent is a proteolytic.

5. A method according to claim 1 wherein the agent is a photolytic agent.

6. A method according to claim 1 wherein the agent is a magnelytic agent.

7. A method according to claim 1 wherein the agent is administered using a technique selected from the group consisting of topically, intravenously, orally, and mucosally.

8. A method according to claim 1 wherein the agent is administered via a route selected from the group consisting of rectal suppositories, nasal sprays, optic drops, topical formulations, vaginal compositions and intravenous composition.

9. A method according to claim 1 wherein the agent is administered via a rectal suppository.

10. A method according to claim 1 wherein the agent is administered via a route selected from the group consisting of nasal sprays and inhalers.

11. A method according to claim 1 wherein the agent is administered via optic drops.

12. A method according to claim 1 wherein the agent is administered via a vaginal composition.

13. A method according to claim 1 wherein the agent is administered via an intravenous composition.

14. A method according to claim 1, wherein said fibrinolytic is administered at a concentration in the range of about 0.1 mg/ml to about 2 mg/ml in a physiologically acceptable solution.

15. A method according to claim 1 wherein the fibrinolytic agent is selected from the group consisting of Serrapeptase and Nattokinase.

16. A method according claim 15 wherein 5000 IU (international units) of Serrapeptase is administered is administered orally in the form of one to four tablets three times daily.

17. A method according claim 15 wherein 5000 IU of Nattokinase is administered orally in the form of one to four tablets three times daily.

18. A method according to claim 15, wherein the agent is formulated to comprise, per 30 mls., a composition selected from the group consisting of serrapeptase 10-50,000 IU, nattokinase 10-50,000 IU, lipase 10-50,000 IU, Rutin 10-50,000 IU, amla 10-50,000 IU, other proteases, and fibrinolytics.

19. A method according to claim 8, wherein,

the agent is formulated for mucosal or vaginal or rectal administration;

the agent comprises a solution having the components mixed in a sterile solution of water producing a concentration of about 0.1% to 5%;

wherein stronger or weaker solutions may be used to reduce or enhance effects; and

wherein other mixing agents may be used to enhance absorption transdermally.

20. A method according to claim 1 wherein the agent is formulated for pulmonary and nasal administration wherein the agent is—delivered by a lung and nasal vaporizer inhaler (respectively) in a metered dosing mechanism.

21. A method according to claim 10 wherein the inhaler contains a composition selected from the group consisting of serrapeptase 10-50,000 IU, nattokinase 10-50,000 IU, lipase 10-50,000 IU, Rutin 10-50,000 IU amla 10-50,000 IU; other proteases, and mixtures thereof.

22. A method according to claim 1 wherein the agent is formulated for veterinary use.

23. A method according to claim 22 to treat consumable animal meat, said method comprising administering an effective amount of the agent to dissolve protein deposited in skeletal muscles, organs or tissues of farm animals to improve or increase perceived improved quality of farm animal products and/or quality of life.